Note 9 - Subsequent Events	9 Months Ended
Sep. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	9. Subsequent Events The ongoing COVID-19 pandemic is disrupting our business operations, which we expect to continue throughout the remainder of 2020 and possibly beyond. We have experienced actual disruption to our supply chain regarding our ability to single use consumables, gloves andmasks, all of which are required in our manufacturing and/or clinical and drug discovery operations. Although we concluded that COVID-19 did not result in material adverse impacts on the Company’s results of operations and financial position at September 30, 2020, if supply disruptions and purchase reductions continue, our clinical manufacturing revenue will be, and our clinical trial service revenue could be, adversely impacted. In addition, social distancing restrictions imposed by national, state and local governments have required adjustments to staffing levels and may impact the willingness of employees to work in laboratory, manufacturing and clinical settings, even after these orders and restrictions are relaxed or allowed to expire. Ongoing restrictions and other disruptions related to COVID-19 could delay our efforts to identify, manufacture, enter into clinical studies, seek regulatory approvals or otherwise commercialize any product candidates. The company signed a licensing agreement with Bio Bridge Global, a Texas nonprofit and its subsidiary South Texas Blood and Tissue Center located in San Antonio to out license an ELISA methodology for detecting and quantifying antibodies against SARS-COV-2. Under this agreement allows BBG to provide blood products and services based on use of XBiotech’s testing technology for detecting COVID-19 antibodies.

Note 9 - Subsequent Events

9 Months Ended

Sep. 30, 2020

9. Subsequent Events

The ongoing COVID-19 pandemic is disrupting our business operations, which we expect to continue throughout the remainder of 2020 and possibly beyond. We have experienced actual disruption to our supply chain regarding our ability to single use consumables, gloves andmasks, all of which are required in our manufacturing and/or clinical and drug discovery operations. Although we concluded that COVID-19 did not result in material adverse impacts on the Company’s results of operations and financial position at September 30, 2020, if supply disruptions and purchase reductions continue, our clinical manufacturing revenue will be, and our clinical trial service revenue could be, adversely impacted. In addition, social distancing restrictions imposed by national, state and local governments have required adjustments to staffing levels and may impact the willingness of employees to work in laboratory, manufacturing and clinical settings, even after these orders and restrictions are relaxed or allowed to expire. Ongoing restrictions and other disruptions related to COVID-19 could delay our efforts to identify, manufacture, enter into clinical studies, seek regulatory approvals or otherwise commercialize any product candidates.

The company signed a licensing agreement with Bio Bridge Global, a Texas nonprofit and its subsidiary South Texas Blood and Tissue Center located in San Antonio to out license an ELISA methodology for detecting and quantifying antibodies against SARS-COV-2. Under this agreement allows BBG to provide blood products and services based on use of XBiotech’s testing technology for detecting COVID-19 antibodies.